Baird analysts stay Neutral on biotech sector as 2019 gets underway
Baird analysts forecast that there will be as many headwinds for the biotech sector as tailwinds in 2019 and say they are sticking to a Neutral outlook on the sector, according to a new research note.
While the speed of the sell-off in biotech shares at the end of 2018 means they could see “a bit of a bounce” and Bristol-Myers Squibb’s (NYSE:BMY) move to buy Celgene (NASDAQ:CELG) for $74 billion has generated a flurry of attention, Baird’s Brian Skorney and Michael Ulz “just don’t see much reason” for the sector to re-rate.
READ: Biotech CEOs see Bristol-Myers’ $74B acquisition of Celgene as a win
“The end of 2018 did not go well, and biotech investors remain a bit shell-shocked,” Skorney and Ulz wrote in a note to investors. “With more FDA approvals, but lower peak sales for drugs on the horizon, it’s hard for us to get more excited than we were at the beginning of last year.”
On the mergers and acquisitions front, it remains unclear whether the marriage of Bristol-Myers Squibb and Celgene will “change the tune” in the sector. And Skorney and Ulz predict that consolidation is more likely to come in the large-cap space and are not betting on a surge in smaller deals.
Sector offers diamonds in the rough for stock pickers
But when it comes to picking biotech stocks, Skorney and Ulz argue that there are some diamonds in the rough.
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) remains Skorney’s top large-cap pick as he thinks growth investors will look to increase stakes in one of the few S&P 500 names that is “really growing.”
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) is also on Skorney’s list of bets as its REGENERATE Phase 3 data could become a catalyst to support the first-approved drug to treat nonalcoholic steatohepatitis (NASH), a type of non-alcoholic fatty liver disease.
Aimmune Therapeutics Inc (NASDAQ:AIMT) is Skorney’s final pick. Its lead investigational drug, AR101 for peanut allergies, is in the final stages of clinical testing to support regulatory approval. “AR101 approval should catalyze enthusiasm for a second half of 2019 launch of the first treatment for peanut allergy,” concludes Skorney.
Ulz’s top stock pick in the sector, meanwhile, is BioMarin Pharmaceutical Inc (NASDAQ:BMRN) thanks to its strong, diversified base business and the promise of its drug valrox, which treats hemophilia A as well as vosoritide, which takes aim at achondroplasia, the most common form of dwarfism.
–Contact Ellen Kelleher at [email protected]
Story by ProactiveInvestors
Source: https://www.proactiveinvestors.com/companies/news/211977/baird-analysts-stay-neutral-on-biotech-sector-as-2019-gets-underway-211977.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation.
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video).